Co-led (with Forbion) Corsera Health's $80M Series A financing for a preventive cardiovascular RNAi therapeutic.
Corsera Health is redefining the future of health by enabling earlier prediction of atherosclerotic cardiovascular disease (ASCVD) and developing a once-annual RNAi medicine to prevent cumulative damage to the cardiovascular system
Corsera Health is redefining the future of health by enabling earlier prediction of atherosclerotic cardiovascular disease (ASCVD) and developing a once-annual RNAi medicine to prevent cumulative damage to the cardiovascular system.